Roivant Sciences Ltd. (NASDAQ: ROIV ) continues executing its "Vant" biotech business model. In short, this approach enables the rapid development of drug candidates and their monetization through subsidiaries focused on specific medical areas. Since my previous article, ROIV’s trials have made promising progress onMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer scienc ...